



# J. B. CHEMICALS & PHARMACEUTICALS LIMITED

September 30, 2019

BSE Ltd.  
Phiroze Jeejebhoy Towers  
Dalal Street  
Mumbai 400 001

**BSE Scrip Code : 506943**

**Stock Symbol: JBCHEPHARM**

Dear Sir,

**Sub: News about presence of NDMA in Ranitidine**

We refer to the recent news about presence of impurity, N-nitrosodimethylamine (NDMA) in active pharmaceutical ingredient (API) Ranitidine.

We are manufacturers of Rantac™ formulations where Ranitidine API is manufactured by third party vendors.

Following this news, our API vendors have got their product analyzed as per international guidelines to verify the presence of NDMA. They have reported that the NDMA is well within the permissible limits.

In addition, the Company has also initiated analysis of the samples of all Rantac formulations for the presence of NDMA. We have to inform that initial report received indicate NDMA is well within the permissible limit.

As a responsible supplier of Rantac, we always take and shall continue to take all steps necessary for patient's safety including those directed by the Drugs Controller General (India). We wish to add that Rantac is being marketed by the Company for over 3 decades and so far no serious adverse events have been reported. We continue to manufacture and sell the product as per the approved regulatory specifications.

Thanking you,

Yours faithfully,

for J. B. Chemicals & Pharmaceuticals Limited

**M. C. Mehta**  
**Company Secretary & Vice President - Compliance**

**Registered Office:**  
Neelam Centre, B Wing, 4th Floor  
Hind Cycle Road, Worli  
Mumbai - 400 030

**Corporate Office:**  
Energy IT Park  
Unit A2, 3rd Floor, Unit A, 8th Floor  
Appa Saheb Marathe Marg, Prabhadevi  
Mumbai - 400 025

☎ +91 22 2439 5200 / 2439 5500  
☎ +91 22 2431 5331 / 2431 5334  
@ info@jbcpl.com  
🌐 www.jbcpl.com  
CIN: L24390MH1976PLC019380